Abstract
Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative “endothelial progenitor cells” (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed “EPCs”, including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of “EPCs” in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.
Keywords: Cell therapy, cardiovascular disease, cell dysfunction, endothelial progenitor cells, diabetes, hypertension, ROS, angiogenesis, macrovasculature, kallikrein-kinin-system
Current Vascular Pharmacology
Title: “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Volume: 10 Issue: 1
Author(s): Nicolle Krankel, Thomas F. Luscher and Ulf Landmesser
Affiliation:
Keywords: Cell therapy, cardiovascular disease, cell dysfunction, endothelial progenitor cells, diabetes, hypertension, ROS, angiogenesis, macrovasculature, kallikrein-kinin-system
Abstract: Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative “endothelial progenitor cells” (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed “EPCs”, including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of “EPCs” in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.
Export Options
About this article
Cite this article as:
Krankel Nicolle, F. Luscher Thomas and Landmesser Ulf, “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease, Current Vascular Pharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157016112798829832
DOI https://dx.doi.org/10.2174/157016112798829832 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Calcium Ions in Inherited Cardiomyopathies
Medicinal Chemistry Distribution of Left Ventricular Thrombus among Patients with Significantly Impaired Systolic Function
New Emirates Medical Journal Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design The Role of Circadian Rhythms in Fatal Arrhythmias and the Potential Impact of Intervention for Sleep-Disordered Breathing
Current Pharmaceutical Design Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Perioperative Management of Obese Parturients
Current Women`s Health Reviews The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews